Journal of International Oncology››2014,Vol. 41››Issue (2): 147-149.doi:10.3760/cma.j.issn.1673-422X.2014.02.020
Previous ArticlesNext Articles
Zhao Zhiwei, Piao Daxun, Jiang Tao, Zhang Zhenan, Wang Jianbing, Jing Qiongyou
Received:
2013-08-19Revised:
2013-10-20Online:
2014-02-08Published:
2014-01-26Contact:
Piao Daxun E-mail:piaodaxun@sina.comZhao Zhiwei, Piao Daxun, Jiang Tao, Zhang Zhenan, Wang Jianbing, Jing Qiongyou. Expressions of IL-6 and IL-8 in normal gastric tissue, gastric ulcer and gastric cancer[J]. Journal of International Oncology, 2014, 41(2): 147-149.
[1] Park JI, Lee MG, Cho K, et al. Transforming growth factorβ1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38, NF-κB, JNK, and Ras signaling pathways[J]. Oncogene, 2003, 22(28): 4314-4332. [2] Bergis D, Kassis V, Ranglack A, et al. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma[J]. Transl Oncol, 2013, 6(3): 311-318. [3] Rafrafi A, Chahed B, Kaabachi S, et al. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: a case control study[J]. Hum Immunol, 2013, 74(10): 1368-1374. [4] Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Haras oncogene product in normal, benign, and malignant human pancrestic tissue[J]. Hum Pathol, 1990, 21(6): 607-612. [5] 陈友康, 龚谋春. 胃癌根治术后血浆中细胞因子的变化及临床意义[J]. 实用临床医药杂志, 2009, 13(12): 105-106. [6] 李冰, 陈凛. 癌组织中IL6、IL6R及PCNA的检测及临床意义[J]. 山东医药, 2008, 48(14): 1-2. [7] 包怀鸣, 陈志荣. 血清IL6、IL8在胃癌中的表达及意义[J]. 中国煤炭工业医学杂志, 2008, 11(6): 838-839. [8] 周春红, 蒋茜, 盛月华, 等. 胃癌患者血清TNF、IL2、IL6检测[J]. 齐齐哈尔医学院学报, 2009, 30(18): 2237-2238. [9] Yae S, Takahashi F, Yae T, et al. Hochuekkito (TJ41), a Kampo formula, ameliorates cachexia induced by colon 26 adenocarcinoma in mice[J]. Evid Based Complement Alternat Med, 2012, 2012: 976926. [10] Wu Y, Fan Y, Jiang Y, et al. Analysis of risk factors associated with precancerous lesion of gastric cancer in patients from eastern China: a comparative study[J]. J Cancer Res Ther, 2013, 9(2): 205-209. [11] 王跃华, 江志伟, 汪志明. 胃癌恶病质病人机体组成与细胞因子的相关性研究[J]. 肠外与肠内营养, 2009, 16(5): 286-287. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[7] | Zhang Li, Xiang Zhuo, Wang Qiang, Bi Jingwang.Research progress of cytokine release syndrome related to CAR-T immunotherapy[J]. Journal of International Oncology, 2023, 50(6): 377-381. |
[8] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[9] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[10] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[11] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[12] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[13] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[14] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[15] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||